Drugmaker Eli Lilly posted a sharp drop in first-quarter profits.
The Indianapolis company saw declining sales of its flagship antidepressant Prozac, which has been facing generic competition since August.
The company said it sees fairly flat earnings for the full year, although results could hit the higher end of analyst expectations. For next year, it expects profit growth to rebound to a high-teen percentage rate, helped by launches of new drugs.
First-quarter earnings fell to $629.2 million, or 58 cents per share, from $806.8 million, or 74 cents per share, a year earlier.
Sales fell 9 per cent to $2.56 billion as Prozac revenues tumbled 70 per cent to $186.1 million.
The results represent the third consecutive earnings decline for Lilly, which has struggled to overcome the loss of US patent protection for Prozac last year.